Market PotentialConsidering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.
Product EfficacyCingulate's CTx-1301 demonstrated potential best-in-class onset and duration for ADHD, making it a competitive differentiator amidst ongoing stimulant shortages.
Regulatory ProgressFDA suggests Cingulate may file NDA for CTx-1301 with existing data, indicating sufficient data is already available for submission.